AVT Stock Recent News

Avnet, Inc. (NASDAQ:AVT ) Q2 2025 Earnings Conference Call January 29, 2025 11:00 AM ET Company Participants Joseph Burke - Vice President, Treasurer & Investor Relations Philip Gallagher - Chief Executive Officer Ken Jacobson - Chief Financial Officer Conference Call Participants Toshiya Hari - Goldman Sachs William Stein - Truist Securities Joe Quatrochi - Wells Fargo Ruplu Bhattacharya - Bank of America Operator Welcome to the Avnet Second Quarter Fiscal Year 2025 Earnings Call. I would now like to turn the floor over to Joe Burke, Vice President Treasury and Investor Relations for Avnet.

Although the revenue and EPS for Avnet (AVT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Avnet (AVT) came out with quarterly earnings of $0.87 per share, missing the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $1.40 per share a year ago.

PHOENIX--(BUSINESS WIRE)-- #Avnet--Avnet to report second quarter fiscal year 2025 earnings on January 29.

Avnet (AVT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

MELBOURNE, Australia--(BUSINESS WIRE)---- $AVT #Avnet--Avnet has been awarded the contract to supply Huizhong's SCL61H-100 smart ultrasonic water meters to South East Water (SEW).

PHOENIX--(BUSINESS WIRE)-- #Avnet--Avnet names Ginnie Henkels and Helmut Gassel to its Board of Directors.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept). The process to obtain marketing authorization could be completed in the third quarter of 2025.

REYKJAVIK, Iceland and LONDON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept). The process to obtain marketing authorization could be completed in the third quarter of 2025.

Explore how Avnet's (AVT) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.